Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Small Cell Lung Carcinoma 23Lymphoma, Non-Hodgkin 18Leukemia, Myeloid, Acute 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lung Neoplasms 15Leukemia 13Carcinoma, Non-Small-Cell Lung 13Burkitt Lymphoma 13Recurrence 9Multiple Myeloma 9Lymphoma, Follicular 8Hodgkin Disease 8Leukemia, Lymphocytic, Chronic, B-Cell 7Congenital Abnormalities 7Lymphoma, B-Cell 6Sarcoma 5Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasms, Plasma Cell 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

Filgrastim 3Carboplatin 3sodium thiosulfate 2etoposide phosphate 2Radiotherapy 2Cyclophosphamide 2Amifostine 2pegfilgrastim 1glucarpidase 1Triptorelin Pamoate 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Melphalan 1Mannitol 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cytarabine 1Cisplatin 1Celecoxib 1Capecitabine 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Drug-Related Side Effects and Adverse Reactions × Etoposide × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡